Samsung Biologics secures half of Japans top 10 pharmas as clients
seoul [South Korea]: Samsung Biologics Co is accelerating its expansion in Japan, the world’s third-largest pharmaceutical market. According to the report of Maeil Business Newspaper Korea’s English service Pulse, the South Korean company has rapidly strengthened its presence in the region by signing contracts with half of Japan’s 10 largest pharmaceutical and biotechnology companies.
“We have signed contracts with four of Japan’s 10 largest pharmaceutical companies, and we are in final negotiations with one more company,” the report quoted Samsung Biologics CEO John Rim as saying at BioJapan 2025 held in Yokohama on Thursday. The statement was included.
“BioJapan is a very important event for us. Cooperation with Japanese companies is essential to expand our customer base from the global top 20 to the top 40 pharmaceutical companies. That is why we established a sales office in Tokyo and sent dedicated sales personnel,” he added.
Japan ranks third globally after the United States and Europe with its strong technological capabilities in antibody-drug conjugates and cell and gene therapies.
Japan’s contract development and production organization market is estimated to grow at an annual rate of 6.8 percent, from US$12.3 billion in 2023 to US$19.5 billion by 2030, according to Research and Markets.
“Demand for CDMO services in Japan is increasing and our potential partnerships with major Japanese pharmaceutical companies are expanding,” Rim said in the report. “We are focusing on antibodies and ADC projects while building trust through face-to-face meetings.”
“The company recently raised its annual revenue growth forecast from 20-25 percent to 25-30 percent, indicating that this year’s revenue could reach approximately 6 trillion won, up from 4.55 trillion won in 2024,” the report said.
Regarding possible expansion to the US, Rim took a cautious stance in the face of tariff uncertainties.
“We are constantly examining potential entry into the US market, and this possibility is higher than it was two to three years ago,” Rim said in the report. “But since labor and construction costs in the U.S. are 70 percent higher than in Korea, we will make our decisions after carefully evaluating demand, tariffs and process efficiency.”
Plant 5, recently launched by Samsung Biologics, strengthens the smart factory infrastructure by integrating automation and artificial intelligence technologies.
This article was generated from an automated news agency feed without modifications to the text.
